Zevra Therapeutics, INC DEF 14A proxy statements

Zevra Therapeutics announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and board declassification.

All three leading proxy advisory firms recommend Zevra stockholders vote for the company's director nominees and withhold on dissident nominees at the upcoming Annual Meeting.

Zevra Therapeutics urges stockholders to vote for its nominees amidst a proxy battle with an activist investor, highlighting its recent achievements and strategic plan.

Daniel J. Mangless is soliciting proxies to elect two new directors to Zevra Therapeutics' board, aiming to address what he views as poor governance and excessive executive compensation.

Zevra Therapeutics files its definitive proxy statement for the 2025 annual meeting, advocating for the re-election of Tamara Favorito and Wendy Dixon, Ph.D. to the Board and addressing alternative director nominees.

Zevra Therapeutics files its definitive proxy statement, urging stockholders to vote for its director nominees to defend board independence against a 2.8% stockholder seeking to gain majority control.

Zevra Therapeutics is urging stockholders to vote for its director nominees, Wendy Dixon and Tamara Favorito, amidst a proxy contest initiated by Daniel J. Mangless.

Zevra Therapeutics issues guidance to employees regarding social media activity during an ongoing proxy contest, emphasizing the importance of compliance and neutrality.

Zevra Therapeutics has filed its preliminary proxy statement, announcing director nominees and addressing a potential proxy contest initiated by a stockholder.

Zevra Therapeutics is addressing a proxy contest initiated by a stockholder proposing alternative director nominees for the upcoming 2025 annual meeting.

Zevra Therapeutics' CEO, Neil F. McFarlane, outlines the company's progress in building a rare disease portfolio, strengthening its financial position, and enhancing corporate governance in a letter to stockholders.

Zevra Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Zevra Therapeutics is holding its 2024 Annual Meeting of Stockholders on May 13, 2024, to vote on director elections, ratification of the accounting firm, executive compensation, and amendments to the equity incentive plan.